Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202608088 A randomized, open-label (unblinding), crossover bioequivalence study to compare two ropinirole HCl PR tablets in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
N202608089 A randomized, open-label (unblinding), crossover bioequivalence study to compare two ropinirole HCl PR tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202608095 External Validation of an X-ray–Based Sarcopenia Prediction Model New Medical Device NA
N202609001 A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination with Other Therapies and Are Continuing ONO-4538 Treatment New Drug Phase Ⅱ
N202609002 A Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of add-on lunsekimig in adolescents and adults with uncontrolled severe asthma New Drug Phase Ⅲ
N202609003 A Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of add-on lunsekimig in adolescents and adults with uncontrolled severe asthma New Drug Phase Ⅲ
N202609006 A randomized, open-label (unblinding), three-period, reference-replicated, crossover bioequivalence study to compare two agomelatine F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202609022 An Open-Label, Randomized, and Crossover Bioequivalence Study of Dapagliflozin 10 mg Film-Coated Tablet in Healthy Subjects under Fasting Conditions New Drug Academic Research
N202609029 An Open-Label, Randomized, and Crossover Bioequivalence Study of Saxagliptin/Dapagliflozin 5/10 mg Film-Coated Tablet in Healthy Subjects under Fasting Conditions New Medical Device NA
N202609037 A preliminary bioequivalence study to compare two 40 mg lurasidone HCl tablets in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
1 2 23 24 25 26 27 28 29 30 31 32 / 32

TOP